Recombinant Human ERBB3 Protein (Ser20-Gly538), C-6×His-tagged
Product Description
Cat
IMP-9584
Official Symbol
ERBB3
Product Overview
Recombinant human ErbB3/Her3 protein (Ser20-Gly538) with a 6×His tag at C-terminus was expressed in Human embryonic kidney cell.
Description
This gene encodes a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. This membrane-bound protein has a neuregulin binding domain but not an active kinase domain. It therefore can bind this ligand but not convey the signal into the cell through protein phosphorylation. However, it does form heterodimers with other EGF receptor family members which do have kinase activity. Heterodimerization leads to the activation of pathways which lead to cell proliferation or differentiation. Amplification of this gene and/or overexpression of its protein have been reported in numerous cancers, including prostate, bladder, and breast tumors. Alternate transcriptional splice variants encoding different isoforms have been characterized. One isoform lacks the intermembrane region and is secreted outside the cell. This form acts to modulate the activity of the membrane-bound form. Additional splice variants have also been reported, but they have not been thoroughly characterized.
Expression System
HEK293
Species
Human
Tag
C-6×His
Predicted N Terminal
Ser20
Form
Lyophilized from a 0.2 μm filtered solution in PBS.
Molecular Mass
Predicted Molecular Mass: 61 kDa
SDS-PAGE: 73-83 kDa, under reducing conditions
Protein length
Ser20-Gly538
Bio-activity
Measured by its ability to inhibit the biological activity of Neuregulin-1-beta 1 on MCF-7 human breast cancer cells. The ED50 for this effect is 0.3-3 μg/mL in the presence of 10 ng/mL Recombinant Human NRG1-beta 1/HRG1-beta 1 Extracellular Domain.
Endotoxin
<1.0 EU/μg of the protein by the LAL method.
Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie Blue Staining.
Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 centigrade as supplied.
1 month, 2 to 8 centigrade under sterile conditions after reconstitution.
3 months, -20 to -70 centigrade under sterile conditions after reconstitution.
Reconstitution
Reconstitute at 500 μg/mL in PBS.
SDS-PAGE
SDS-PAGE

Bioactivity-ELISA 1
Bioactivity

Measured by its ability to inhibit the biological activity of Neuregulin-1-beta 1 on MCF-7 human breast cancer cells. The ED50 for this effect is 0.3-3 μg/mL in the presence of 10 ng/mL Recombinant Human NRG1-beta 1/HRG1-beta 1 Extracellular Domain.

Data Sheet MSDS
For research or industrial raw materials, not for personal medical use!

Online Inquiry
Contact Info